What Is AOD-9604?
AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (HGH) consisting of amino acids 176–191 of the HGH peptide chain, with a tyrosine addition at the N-terminus. It was originally developed by Monash University in Australia as a safer alternative to HGH for treating obesity.
The key insight behind AOD-9604 is that the fat-mobilizing effects of HGH are concentrated in this specific C-terminal fragment — while the anabolic and blood-sugar-raising effects of HGH are associated with other regions of the molecule. By isolating fragment 176–191, researchers created a compound that triggers lipolysis (fat breakdown) without the IGF-1-mediated growth effects or the hyperglycemia associated with full-length HGH.
How AOD-9604 Works
Stimulating Lipolysis
AOD-9604 binds to beta-3 adrenergic receptors on fat cells, activating hormone-sensitive lipase — the enzyme that mobilizes stored triglycerides from adipocytes. This releases free fatty acids into circulation for use as fuel. The effect is similar to the fat-burning action of exercise-induced catecholamines, but specifically targeted at adipose tissue.
Inhibiting Lipogenesis
Simultaneously, AOD-9604 inhibits the conversion of non-fat foods into new fat stores — the process of de novo lipogenesis. This dual action (more fat breakdown, less new fat creation) makes it particularly effective for patients with diet-resistant adiposity.
Mimicking HGH's Fat Effects Without the Side Effects
Full-length HGH does produce significant fat loss, but also causes fluid retention, joint pain, insulin resistance, and potential IGF-1-related tumor promotion risk with long-term use. AOD-9604 avoids all of these because it doesn't activate IGF-1 pathways and has a high safety profile in clinical trials.
Clinical Evidence for AOD-9604
AOD-9604 has been studied in multiple human clinical trials, most conducted in the 1990s and early 2000s through Monash University and the pharmaceutical company Metabolic Pharmaceuticals.
Phase II/III Clinical Trials
A 24-week placebo-controlled trial in 300 obese adults found that oral AOD-9604 at 1 mg/day produced statistically significant fat loss compared to placebo, with no significant effects on blood glucose, IGF-1 levels, or other growth-related parameters. The compound also demonstrated an excellent safety profile with no serious adverse events attributed to the drug.
While Phase III trials for FDA approval ultimately did not achieve their primary endpoints (likely due to formulation issues with oral delivery), injectable AOD-9604 has continued to be studied and used in clinical settings where bioavailability is not compromised by oral administration.
Animal Studies
Robust animal data across multiple species confirms AOD-9604's fat-mobilizing effects. In obese mice, it produced a 50% reduction in fat mass over 8 weeks without affecting lean muscle mass or blood glucose.
AOD-9604 for Stubborn Fat and Plateaus
Clinically, AOD-9604 is most commonly considered for:
- Plateau-breaking: Patients who have lost significant weight but hit a fat loss plateau resistant to further caloric restriction
- Body recomposition: Reducing fat mass while preserving or building muscle — particularly relevant for patients also using peptides like CJC-1295/Ipamorelin
- Visceral and stubborn adiposity: Including abdominal fat that is hormonally resistant to diet and exercise
- Post-GLP-1 maintenance: After weight loss with semaglutide or tirzepatide, supporting ongoing fat metabolism during the maintenance phase
Learn more about our comprehensive peptide therapy guide and how peptides can be strategically combined.
AOD-9604 vs. Other Fat Loss Peptides
AOD-9604 vs. CJC-1295/Ipamorelin Stack
The CJC-1295/Ipamorelin stack stimulates GH secretion broadly, producing fat loss, muscle gain, and improved sleep. AOD-9604 targets fat loss more directly without affecting GH pulsatility. Many protocols combine both: the GH-secreting stack for its broad anabolic and recovery benefits, with AOD-9604 added specifically for targeted fat mobilization.
Read our in-depth comparison of ipamorelin and CJC-1295 stacking.
AOD-9604 vs. Full HGH
Full-length HGH is more powerful for muscle gain and anti-aging effects but carries more risk, requires careful dosing, and is significantly more expensive. AOD-9604 is fat-loss-specific, safer, and more affordable. They serve different primary goals.
Dosing and Administration
AOD-9604 is administered subcutaneously (under the skin) in clinical peptide programs. Typical protocols use 250–300 mcg daily, administered in the morning on an empty stomach to maximize GH-axis sensitivity. A 12-week cycle is common, with breaks to prevent receptor desensitization.
Oral formulations exist but have significantly lower bioavailability. Injectable AOD-9604 under clinical supervision produces more reliable and consistent results.
Safety Profile
AOD-9604 has one of the cleanest safety profiles of any weight-loss-focused peptide or drug. It does not raise blood glucose, does not affect IGF-1, does not cause fluid retention, and has demonstrated no serious adverse effects across multiple clinical trials. It received GRAS (Generally Recognized as Safe) status from the FDA as a food ingredient.
As with all peptides, it should be obtained from a compounding pharmacy under clinical supervision to ensure proper sterility, dosing, and purity.
Ready to take control of your health?
Connect with a licensed clinician from home. No waiting rooms, no hassle.
Start Free Consultation